Brambilla Roberta, Cottini Lorenzo, Fumagalli Marta, Ceruti Stefania, Abbracchio Maria P
Department of Pharmacological Sciences, University of Milan, Milan, Italy.
Glia. 2003 Aug;43(2):190-4. doi: 10.1002/glia.10243.
Previous literature data show that blockade of A(2A) adenosine receptors via selective antagonists induces protection in various models of neurodegenerative diseases. The mechanisms underlying this effect are still largely unknown. Since it is known that excessive reactive astrogliosis is a factor contributing to cell death in diseases characterized by neurodegenerative events, the present study has been aimed at determining whether selective A(2A) receptor antagonists can counteract the formation of reactive astrocytes induced in vitro by basic fibroblast growth factor (bFGF), a typical trigger of this reaction. Exposure of primary rat striatal astrocytes to the selective A(2A) antagonist SCH58261 resulted in concentration-dependent abolition of bFGF induction of astrogliosis in vitro. This effect could also be reproduced with the chemically unrelated A(2A) antagonist KW-6002. The direct activation of A(2A) adenosine receptors by selective receptor agonists was not sufficient per se to induce astrogliosis, suggesting that the A(2A) receptor needs to act in concert with other bFGF-induced genes to trigger the formation of reactive astrocytes. These results provide a mechanism at the basis of the neuroprotection induced by A(2A) receptor antagonists in models of brain damage and highlight this adenosine receptor subtype as a novel target for the pharmacological modulation of the gliotic reaction.
先前的文献数据表明,通过选择性拮抗剂阻断A(2A) 腺苷受体可在各种神经退行性疾病模型中诱导产生保护作用。这种效应背后的机制在很大程度上仍然未知。由于已知过度的反应性星形胶质细胞增生是导致以神经退行性事件为特征的疾病中细胞死亡的一个因素,因此本研究旨在确定选择性A(2A) 受体拮抗剂是否能够抵消碱性成纤维细胞生长因子 (bFGF,这种反应的典型触发因素) 在体外诱导产生的反应性星形胶质细胞的形成。将原代大鼠纹状体星形胶质细胞暴露于选择性A(2A) 拮抗剂SCH58261后,可导致bFGF在体外诱导的星形胶质细胞增生呈浓度依赖性消除。使用化学结构不相关的A(2A) 拮抗剂KW-6002也可重现这种效应。选择性受体激动剂对A(2A) 腺苷受体的直接激活本身并不足以诱导星形胶质细胞增生,这表明A(2A) 受体需要与其他bFGF诱导的基因协同作用,以触发反应性星形胶质细胞的形成。这些结果为A(2A) 受体拮抗剂在脑损伤模型中诱导产生神经保护作用提供了一种机制,并突出了这种腺苷受体亚型作为对胶质增生反应进行药理调节的新靶点。